Control of cabozantinib S-malate particle attributes during tablet core manufacture is inseparable from the low aqueous solubility of the salt and the three reference tablet strengths of 20 mg, 40 mg, and 60 mg free base equivalent. The approved tablet label lists anhydrous lactose, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate as core excipients; these components provide dry binding, disintegration, and flow control without introducing an aqueous granulation step. Because cabozantinib S-malate exhibits pH-dependent dissolution, the core formulation must avoid alkaline excipients that could create a localized pH above the salt disproportionation boundary; this restriction is evaluated by fixed-dose compatibility studies under ICH Q8 and confirmed by X-ray powder diffraction per USP <941> to rule out free base formation during blending and compression. Particle size distribution is controlled by laser diffraction per USP <429>, and a tightened D90 criterion is typically justified by content uniformity and dissolution data rather than by a pharmacopeial monograph, since no harmonized USP monograph for cabozantinib S-malate has been published. In low-dose direct compression oncology tablet formulation, croscarmellose sodium is typically used at 2–5% w/w, colloidal silicon dioxide at 0.1–0.5% w/w, and magnesium stearate at 0.5–1.0% w/w, but the approved label for the reference tablet does not declare quantitative composition. The dry blending sequence introduces colloidal silicon dioxide as a glidant before the final lubricant step; magnesium stearate is added at low shear and controlled mixing time to avoid excessive coating of hydrophobic surfaces, which would reduce disintegration and slow dissolution in USP <711> Apparatus II testing. In production-scale bin blenders, pre-lubrication blend uniformity is verified by sampling at multiple locations under 21 CFR 211.110, and the acceptance value is established in accordance with USP <905> uniformity of dosage units. On rotary tablet presses equipped with B-tooling and forced feeders, weight variation, breaking force, and friability are monitored as in-process controls; the friability limit of ≤1.0% after 100 revolutions is applied per USP <1216> to ensure film-coating robustness. Tablet cores that fail the friability threshold or show edge chipping in developmental batches indicate that the formulation requires additional dry binder or reduced punch penetration depth, not necessarily additional lubricant, because cabozantinib S-malate at low dose is prone to segregation when the blend has wide particle size differences. The final film-coated tablet is subjected to assay, related substances, dissolution, and moisture testing; the moisture limit is derived from stability data under ICH Q1A(R2), and the product is stored at 20°C to 25°C per the approved label with excursions to 15°C to 30°C.

What Limits Direct Compression Throughput for Low-Dose Cabozantinib S-Malate Cores?

Direct compression throughput is constrained by blend flow, die filling consistency, and segregation rather than by the intrinsic compressibility of the excipients alone. The label excipients include anhydrous lactose and microcrystalline cellulose, both of which provide acceptable compactability, but their flow behavior changes with storage humidity above 60% RH; pre-drying is required if dynamic vapor sorption analysis shows a weight gain exceeding the limit defined during process qualification, with water content confirmed by USP <921>. In production-scale bin blenders, the pre-lubricated blend is transferred to the press hopper, where particle size differences between the API, lactose, and croscarmellose sodium can produce percolation segregation; this is controlled by maintaining hopper level above the induced feed screw, by limiting transfer steps, and by verifying blend uniformity after each transfer under 21 CFR 211.110. Tablet press parameters are not publicly available for the reference listed drug; process development usually begins with precompression force, main compression force, turret speed, and ejection force monitoring on instrumented rotary presses. For low-dose direct compression formulations, precompression in the range of 2–4 kN followed by main compression in the range of 8–20 kN is common, but these values are formulation-specific and cannot be transferred to cabozantinib S-malate without compaction data. The true limiting factor at scale is the ejection force and sticking tendency; cabozantinib S-malate has no reported sticking in public literature, but the high surface area of the API and the presence of croscarmellose sodium can increase sensitivity to over-lubrication, which retards disintegration. The disintegration test per USP <701> and dissolution test per USP <711> are used to set the lubricant mixing time and press force limits. If dissolution slows after compression at high force, the formulation may require rearrangement of the superdisintegrant or a switch from direct compression to dry granulation, because excessive tablet breaking force cannot be corrected by film coating.

Aqueous Film Coating of Cabozantinib Tablets: Salt Disproportionation Boundary

Aqueous film coating is not a benign finishing step for cabozantinib S-malate tablets because a high-humidity, low-pH microclimate at the tablet surface can drive conversion of the S-malate salt to the free base. The reference tablet coating contains hypromellose, triacetin, titanium dioxide, and iron oxide yellow; the coating dispersions are prepared with purified water and sprayed through an air-atomizing nozzle in a perforated pan under negative pressure. Process parameters that must be controlled include inlet air temperature, exhaust air temperature, pan speed, spray rate, atomization pressure, and dew point; the critical response is not merely visual coat uniformity but the absence of free base formation at the core-coating interface. Salt disproportionation is monitored by X-ray powder diffraction per USP <941> on the core surface after peeling the film, and by dissolution in 0.1 N HCl media per USP <711> to detect any lag phase caused by a free base film. If the aqueous coating process cannot maintain the surface moisture below the critical threshold, an organic solvent coating system based on hypromellose dissolved in an ICH Q3C Class 3 solvent is an alternative; this eliminates the salt disproportionation pathway but requires explosion-proof pan construction and residual solvent testing per USP <467>. The coating endpoint is controlled by weight gain, typically 2–4% for a non-functional film, but the specific weight gain for cabozantinib tablets is product-specific and confirmed by photostability and moisture uptake data. The coated tablets are stored in high-density polyethylene bottles with desiccant, and the label permits excursions to 15°C to 30°C; exposure to high humidity should be avoided because moisture-induced disproportionation is a shelf-life risk, not only a process risk.

Dry Granulation and Roller Compaction Parameters

Roller compaction converts the dry blend into densified ribbons that are milled into granules; this route is selected when direct compression cannot meet content uniformity or flow specifications at the required tablet speed. Cabozantinib S-malate tablets may be produced by dry granulation to avoid water contact entirely, preserving the S-malate salt and preventing hydrate formation. The dry blend excludes magnesium stearate during ribbon formation; the lubricant is added after granulation to avoid excessive brittle fracture of ribbons caused by the hydrophobic lubricant film. Roller compaction is performed on an instrumented roller press capable of controlling roll pressure, roll speed, gap, and screen size for the integrated mill. Ribbon density is the primary process response, measured by pycnometry or envelope volume displacement; if ribbon density is too low, the granules contain excess fines that segregate in the tablet press; if ribbon density is too high, the granules lose compactability and the subsequent tablets may show capping. The mill screen aperture, typically selected between 0.8 mm and 1.5 mm in published pharmaceutical dry granulation studies, is not a universal value and is chosen based on particle size distribution and bulk density; published data for cabozantinib S-malate roller compaction is limited. In-process controls include granule bulk density, tapped density, and sieve analysis per USP <786> for particle size distribution. The final lubricated granulation is compressed into tablet cores using the same B-tooling press train as direct compression, with precompression and main compression adjusted downward if the granules have lower plasticity. The resulting tablet cores can be film-coated with the aqueous process described above, but the lower surface porosity of dry-granulated cores may reduce water penetration and therefore the film-coating spray rate should be re-qualified. The granule route is also suited to capsule filling or sachet filling when a granule presentation is required for enteral administration; no such commercial cabozantinib granule presentation is approved, so any such use would be an unlicensed formulation.

For capsule-based presentations such as the 20 mg and 80 mg free base equivalent cabozantinib capsules, the unit operation must contain a cytotoxic API while achieving fill weight uniformity at low doses. The reference capsule product is classified as a hazardous drug by NIOSH, which drives engineering controls, work practice controls, and closed-system transfer devices under the current NIOSH hazardous drug list. Capsule filling is preferably performed on an intermittent dosator machine or a tamping-pin machine installed inside an isolator with negative pressure and high-efficiency particulate air filtration; the room classification is maintained at ISO 14644-1 Class 8 for oral solid dosage manufacturing under EU GMP, but the isolator interior may be operated at a higher level of cleanliness to protect the product from cross-contamination rather than for sterility. The powder blend for capsule filling requires the same control of segregation and lubrication as tablet blends, with the additional constraint that capsule shells introduce moisture and static charge. Gelatin or hypromellose capsules are selected based on stability data; if gelatine is used, the fill blend must be dry enough to prevent shell brittleness or softening, and the capsule moisture content is controlled by storage at 20°C to 25°C and 40–50% RH. The fill weight uniformity is verified in-process by checkweighing at defined intervals under 21 CFR 211.110, and the finished capsules are tested for assay, related substances, and dissolution per USP <711>. Cross-contamination control is validated by cleaning validation protocols that include swab sampling of the dosator, tamping pins, and powder bed, with acceptance criteria based on toxicological allowed daily exposure and analytical limit of quantification. The final capsule product may contain crospovidone or sodium starch glycolate as disintegrant, but the exact excipients for the reference capsule are not repeated here because they differ from the tablet formulation; identification and assay of the capsule contents rely on the same chromatographic method validated under ICH Q2(R1).

When Lyophilized Injectable Cabozantinib Requires pH Adjustment and Solubilizer Selection, Cycle Development Follows

Feasibility studies for an injectable product begin with equilibrium solubility screening in buffered media because cabozantinib S-malate has limited solubility in water and in physiologically compatible pH ranges. No FDA-approved parenteral presentation exists as of 2025, so formulation development is de novo and must establish all critical quality attributes without reference to an Orange Book formulation. The S-malate salt may dissolve more rapidly than the free base in acidic media, but upon dilution with plasma or phosphate buffer the free base can precipitate; therefore a solubilization strategy is required for intravenous administration. Approaches evaluated in published early-phase oncology formulations include co-solvent systems such as polyethylene glycol and propylene glycol, cyclodextrin complexation, and nanosuspensions produced by high-pressure homogenization or wet media milling. Each approach imposes its own process constraints: co-solvent systems require tonicity adjustment with sodium chloride or dextrose and may cause injection site reactions; cyclodextrin systems require renal clearance considerations and osmolality control; nanosuspensions require steric stabilization and particle size control by dynamic light scattering or laser diffraction per USP <429>. If a lyophilized formulation is pursued, a bulking agent such as mannitol or trehalose is evaluated at concentrations typically between 2% w/v and 5% w/v; the choice is made by cake appearance and collapse temperature. The lyophilized formulation is developed only after the solution or suspension formulation has shown acceptable chemical stability in the liquid state during the processing window. Lyophilization cycle development uses a freeze-dryer with controlled shelf temperature, condenser temperature, and pressure; the critical process parameters include freezing rate, annealing temperature, primary drying shelf temperature and chamber pressure, secondary drying temperature, and final cake temperature. Collapse temperature is measured by freeze-drying microscopy or differential scanning calorimetry; the primary drying shelf temperature is set below the collapse temperature determined for the specific formulation. The finished lyophilized cake is tested for appearance, reconstitution time, moisture per USP <921>, assay, related substances, pH, osmolality, sterility per USP <71>, endotoxin per USP <85>, and subvisible particulate matter per USP <788>. Container closure integrity is verified by vacuum decay or dye ingress per USP <1207>, and residual solvents are controlled per ICH Q3C and tested by USP <467>. The drug substance used for injectable manufacturing must meet tighter elemental impurity limits than oral grades under ICH Q3D, and vendor certificates for palladium, chromium, nickel, and arsenic are evaluated against the parenteral permitted daily exposure. Processing is conducted under EU GMP Annex 1 in a Grade A unidirectional airflow with Grade B background; aseptic filtration uses a 0.22 µm membrane filter unless the formulation is a nanosuspension that may require a larger prefilter and a validated bioburden-reduction filtration step. If the formulation contains liposomes or polymeric micelles, filter integrity testing must be paired with particle size analysis before and after filtration to detect any filter-induced aggregation. Published data for this specific injectable cabozantinib configuration is limited; therefore formulation selection must be based on internal screening under ICH Q8 and not on direct transfer from the oral solid dosage form.

Aseptic processing of cabozantinib injectable formulations eliminates the terminal sterilization step when moist heat at 121°C for 15 min is precluded by degradation observed in forced-degradation studies under ICH Q1B. The process stream is therefore sterilized by filtration through a 0.22 µm sterilizing-grade membrane; filter pairs may include a polyethersulfone or polyvinylidene fluoride membrane because cabozantinib S-malate can adsorb to certain nylon membranes. Filter adsorption validation is performed with mass balance across the filter train, and the initial filtrate is discarded if the filter matrix retains a measurable fraction of the API. The sterile solution is filled into glass vials or lyophilization vials after depyrogenation at 250°C for 30 min; the filling line is isolated within a restricted access barrier system or isolator. The filling rate must be balanced against the freeze-drying capacity, because partially stopped vials held too long in the loading line may absorb moisture or undergo microbial ingress. After lyophilization, the vials are stoppered under vacuum or nitrogen and sealed with aluminum crimp caps; residual moisture is controlled by Karl Fischer titration per USP <921> with a limit derived from stability data. Subvisible particulate matter is measured by light obscuration per USP <788> after reconstitution; if the formulation is a suspension or nanosuspension, light microscopy per USP <790> is used to distinguish drug particles from foreign particulate. Visible particulate inspection is a 100% manual or semi-automated process under USP <790>; the inspector qualification and defect library must include drug-related particles, glass fragments, and fibers. Stopper compatibility is evaluated by extractables and leachables studies per USP <1663> and USP <1664>; the rubber formulation must not contain leachable compounds that accelerate oxidation or precipitation of cabozantinib in the reconstituted solution. The final injectable product is stored protected from light at 2°C to 8°C if the lyophilized cake shows accelerated degradation at room temperature; the storage condition is assigned only after ICH Q1A(R2) stability protocols. No terminal sterilization and no preservative are added unless a multiple-dose presentation is justified; single-dose vials are preferred for oncology injectables to avoid antimicrobial preservative interaction with the cabozantinib S-malate salt.